Fore Biotherapeutics is a virtual precision oncology company rooted in science and innovation, with expertise and talent across the USA. The company is focused on developing treatments, including its Plixorafenib Program.
Subscribe to see Fore Biotherapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Fore Biotherapeutics is a biotech company headquartered in United States. Its most recent funding round, Series D, raised $67M in July 2026. Xcout tracks 11 named people at Fore Biotherapeutics, including William Hinshaw (Chief Executive Officer and Member of the Board of Directors).
5 more named people on record for Fore Biotherapeutics, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $67M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.